GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (NAS:TRAW) » Definitions » Shiller PE Ratio

Traws Pharma (Traws Pharma) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma Shiller PE Ratio Historical Data

The historical data trend for Traws Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Shiller PE Ratio Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Traws Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Traws Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Shiller PE Ratio falls into.



Traws Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Traws Pharma's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Traws Pharma's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.2/129.4194*129.4194
=-0.200

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -1,957.480 99.695 -2,541.122
201406 -1,732.480 100.560 -2,229.690
201409 -1,552.480 100.428 -2,000.652
201412 -1,394.990 99.070 -1,822.341
201503 -1,282.490 99.621 -1,666.104
201506 -929.241 100.684 -1,194.449
201509 -584.994 100.392 -754.143
201512 407.246 99.792 528.152
201603 -596.244 100.470 -768.043
201606 -440.996 101.688 -561.260
201609 -65.249 101.861 -82.902
201612 -181.301 101.863 -230.348
201703 -276.747 102.862 -348.198
201706 -65.249 103.349 -81.708
201709 -158.999 104.136 -197.603
201712 -131.699 104.011 -163.871
201803 -75.600 105.290 -92.926
201806 -16.500 106.317 -20.085
201809 -14.100 106.507 -17.133
201812 -12.750 105.998 -15.567
201903 -19.350 107.251 -23.350
201906 -9.000 108.070 -10.778
201909 -11.250 108.329 -13.440
201912 -0.775 108.420 -0.925
202003 -0.450 108.902 -0.535
202006 -0.650 108.767 -0.773
202009 -0.520 109.815 -0.613
202012 -0.520 109.897 -0.612
202103 -0.320 111.754 -0.371
202106 -0.270 114.631 -0.305
202109 -0.220 115.734 -0.246
202112 -0.160 117.630 -0.176
202203 -0.200 121.301 -0.213
202206 -0.190 125.017 -0.197
202209 -0.260 125.227 -0.269
202212 -0.260 125.222 -0.269
202303 -0.280 127.348 -0.285
202306 -0.200 128.729 -0.201
202309 -0.230 129.860 -0.229
202312 -0.200 129.419 -0.200

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Traws Pharma  (NAS:TRAW) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Traws Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (Traws Pharma) Business Description

Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Executives
Victor M Moyo officer: CHIEF MEDICAL OFFICER 12 PENNS TRAIL, NEWTOWN PA 18940
Trafford Clarke director 12 PENNS TRAIL, NEWTOWN PA 18940
Peter Atadja director 12 PENNS TRAIL, NEWTOWN PA 18940
Abraham N. Oler officer: VP Corp Dev & Gen Counsel C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052
Steven M Fruchtman officer: Chief Medical Officer 375 PHEASANT RUN, NEWTOWN PA 18940
James J Marino director C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940
Gelder Mark S. Md officer: Chief Medical Officer C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark Patrick Guerin officer: Chief Accounting Officer 375 PHEASANT RUN, NEWTOWN PA 18940
Mary Teresa Shoemaker director 375 PHEASANT RUN, NEWTOWN PA 18940
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831
E Premkumar Reddy director 375 PHEASANT RUN, NEWTOWN PA 18940
Jerome Groopman director C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922
Viren Mehta director OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747
Tyndall Capital Partners L P 10 percent owner 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022

Traws Pharma (Traws Pharma) Headlines